Safety and Immunogenicity Study of an Influenza Vaccination Strategy Including an H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-18 Years Old
Conditions: Influenza; Influenza Immunisation Interventions: Biological: Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine; Biological: Influenza Virus Quadrivalent Inactivated Vaccine; Other: Placebo Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | H3N2 | Infectious Diseases | Influenza | Influenza Vaccine | Pediatrics | Study | Vaccines